Recruiting NCT00935090

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Trial Parameters

Condition Brain and Central Nervous System Tumors

Sponsor Barbara Ann Karmanos Cancer Institute

Study Type INTERVENTIONAL

Phase N/A

Enrollment N/A

Sex ALL

Min Age 18 Years

Max Age 120 Years

Start Date 2009-09

Completion 2027-05

All Conditions

Brain and Central Nervous System Tumors Chronic Myeloproliferative Disorders Leukemia Lymphoma Lymphoproliferative Disorder Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Unspecified Adult Solid Tumor, Protocol Specific

Interventions

3'-deoxy-3'-[18F]fluorothymidine

Brief Summary

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

Eligibility Criteria

DISEASE CHARACTERISTICS: * Meets one of the following criteria: * Histologically confirmed solid tumor or hematologic malignancy * Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging PATIENT CHARACTERISTICS: * Able to lie still in the PET scanner * Girth and weight must be suitable to enter the gantry * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: * Not specified

Related Trials

NCT00935090

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

View Trial →

VIEW ON CLINICALTRIALS.GOV ↗ MORE BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS TRIALS